Treats uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae…. ANDA 213342, held by Accord Hlthcare. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 213342 (Hydroxychloroquine Sulfate), held by Accord Hlthcare, was first approved by FDA on Apr 7, 2020, with 1 approved supplement and 0 published complete response letters.
Hydroxychloroquine sulfate is an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. Treatment of rheumatoid arthritis in adults. >Treatment of systemic lupus erythematosus in adults. Treatment of chronic discoid lupus erythematosus in adults. Limitations of Use: Hydroxychloroquine sulfate is not recommended for the: Treatment of complicated malaria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 7, 2020 | Original application | Approved | None posted |
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Hydroxychloroquine Sulfate100MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Hydroxychloroquine Sulfate300MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Hydroxychloroquine Sulfate400MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Sep 12, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 7, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters